About 400 reports

  • Gastrointestinal Drugs Market Trends And Strategies
  • COST-EFFECTIVE BIOSIMILARS TO TREAT GASTROINTESTINAL DISEASES

The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors,...

  • Digestive System Disorder
  • World
  • Market Size
  • Allergan plc
  • Novo Nordisk Group
  • 2.4 Co-morbidities and Complications
  • 8.4 Abbreviations

Alexion only markets one product in the gastrointestinal therapy area, namely Soliris.

  • Digestive System Disorder
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

Chapter ## provides an introduction to the report.

  • Digestive System Disorder
  • Pathology
  • World
  • Demand
  • MARKET OVERVIEW
  • MARKET CHALLENGES

It is one of the largest manufacturers of gastrointestinal medical devices in the world.

  • Digestive System Disorder
  • World
  • IntroMedic
  • Medtronic, Inc.
  • Olympus Corporation
  • Colorectal cancer
  • Market segmentation by application

About GI stool testing Normal gastrointestinal (GI) functioning is essential for digestion as well as for the removal of body waste and pathogens. GI disorders are a common problem in the general population. These disorders are known to cause severe harm to the health and quality of life of an individual. These disorders include malabsorption...

  • Digestive System Disorder
  • United States
  • World
  • DiaSorin S.p.A.
  • Quidel Corporation
  • 7.2.5 GASTROINTESTINAL DISORDERS
  • HUMAN MICROBIOME MARKET: MARKET SHARE, BY DISEASE, GLOBAL, 2025

The global human microbiome market is expected to account for nearly USD 273.40 million, registering a CAGR of about 22.6% during 2018-2025 (the forecast period). Moreover, the market is expected to reach USD 757.26 million by 2025. Increasing Incidence of Lifestyle Diseases The rising incidence of lifestyle diseases at the global...

  • Digestive System Disorder
  • United States
  • DuPont
  • Enterome Bioscience SA
  • Synlogic, Inc.
  • GASTROINTESTINAL STENTS MARKET: DRIVERS, OPPORTUNITIES, &
  • BILIARY DISEASES TO DOMINATE GASTROINTESTINAL STENTS MARKET,

The gastrointestinal stents market is projected to grow at a CAGR of 5.1% between 2017 and 2022. The gastrointestinal stents market is expected to reach USD 452.6 million by 2022 from USD 353.4 million in 2017, at a CAGR of 5.1% from 2017 to 2022. The rising prevalence of gastrointestinal cancers and other digestive diseases...

  • Ambulatory Care
  • Digestive System Disorder
  • North America
  • United States
  • World
  • A: CAUSES OF NAFLD INFECTION
  • Fatty Liver Disease Market Outlook

THREATS OF SUBSTITUTES - LOW ##.

  • Digestive System Disorder
  • World
  • Gilead Sciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Clinical Trials by E7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015" provides data on the Functional (Non Ulcer) Dyspepsia clinical trial scenario. This report provides elemental information and data...

  • Digestive System Disorder
  • World
  • Actavis plc
  • Astellas Pharma Inc.
  • Zeria Pharmaceutical Co., Ltd.
  • EISAI
  • MARKET OUTLINE

Rating indicates the level of growth opportunities and the green arrows point to the category with high opportunities Impact: ## Low; ## High DAEWOONG PHARMACEUTICALS: OPPORTUNITY ASSESSMENT Assessment Key product Albis It is a combination drug used for the treatment of various

  • Digestive System Disorder
  • Forecast
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • 3.2 Information sources

Impact: ## Low; ## High F.

  • Digestive System Disorder
  • World
  • Forecast
  • Merck & Co., Inc.
  • Pfizer Inc.
  • IBD
  • RHEUMATOID ARTHRITIS

It causes chronic inflammation of any part or the entire gastrointestinal tract.

  • Digestive System Disorder
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Fatty Liver Disease Therapeutics Market, Fatty Liver Disease (Unspecified), Global, Pipeline Products, 2017
  • Fatty Liver Disease Therapeutics Market, Global, Pipeline Products, 2017 (Part 4)

Journal of Physiology: Gastrointestinal and Liver Physiology; ##: ##-## ##(suppl ##): ##-## Folli F, et al. (1999).

  • Digestive System Disorder
  • World
  • Catabasis Pharmaceuticals, Inc.
  • Galectin Therapeutics Inc.
  • Hepatology
  • Market segmentation by types of liver cirrhosis

You can easily book an appointment with one online.

  • Digestive System Disorder
  • Market Size
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Market definition
  • MARKET ECOSYSTEM

You can easily book an appointment with one online.

  • Digestive System Disorder
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • ORAL PROTEINS / PEPTIDES: DISTRIBUTION BY THERAPEUTIC AREA
  • 7.6.1.6. ORAL PROTEINS / PEPTIDES FOR ACROMEGALY

DIGESTIVE AND GASTROINTESTINAL DISORDERS DIGESTIVE AND GASTROINTESTINAL DISORDERS ARE ONE OF THERAPEUTIC AREAS THAT ARE TARGETED BY SEVERAL ORAL PEPTIDE / PROTEIN THERAPEUTICS THAT ARE EITHER MARKETED OR UNDER DEVELOPMENT.

  • Digestive System Disorder
  • North America
  • United States
  • Ironwood Pharmaceuticals, Inc.
  • Novo Nordisk Group
  • Other gastrointestinal disease, total (000s)
  • IBS patients with gastroenteritis, total (000s)

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Irritable Bowel Syndrome in 12 Major Markets Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group of symptoms but includes abdominal pain and disturbed defecation. IBS is divided into several subtypes including: • Diarrhoea predominant...

  • Digestive System Disorder
  • Gastrointestinal Drug
  • OTC
  • Pathology
  • Italy
  • SAFETY OF LOTRONEX - MOST FREQUENTLY REPORTED AES
  • 12.1 BIBLIOGRAPHY

Our Gastrointestinal Portfolio.

  • Digestive System Disorder
  • Allergan plc
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • Ironwood Pharmaceuticals, Inc.
  • PROPORTION OF GASTROINTESTINAL BLEEDING (GASTROINTESTINAL HEMORRHAGE) TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%),
  • PROPORTION OF GASTROINTESTINAL BLEEDING (GASTROINTESTINAL HEMORRHAGE) TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%),

Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Global Clinical Trials Review, H2, 2017" provides an overview of Gastrointestinal Bleeding (Gastrointestinal Hemorrhage)...

  • Digestive System Disorder
  • Hospital
  • Therapy
  • World
  • Product Initiative
  • 3. DEVELOPING H2 RECEPTOR ANTAGONISTS

The demand for Bismuth preparation is limited due to its poor taste. (##)Sucralfate is an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

  • Digestive System Disorder
  • China
  • Demand
  • Trade
  • AstraZeneca PLC
  • Irritable Bowel Syndrome: Executive Summary
  • 4.1 BIBLIOGRAPHY

Gut and Liver; ##(##):##-##.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • OTC
  • Italy
  • Forecast
  • PROPORTION OF REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES
  • Clinical Trials by G7 Countries: Proportion of Reflux Esophagitis (Gastroesophageal Reflux Disease) to Gastrointestinal Clinical Trials

Reflux Esophagitis (Gastroesophageal Reflux Disease) Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Reflux Esophagitis (Gastroesophageal Reflux Disease) Global Clinical Trials Review, H1, 2015" provides an overview of Reflux Esophagitis (Gastroesophageal Reflux Disease) clinical trials...

  • Digestive System Disorder
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Gastrointestinal infection
  • Proportion of Diarrhea to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*

Diarrhea Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Diarrhea Global Clinical Trials Review, H1, 2015" provides an overview of Diarrhea clinical trials scenario. This report provides top line data relating to the clinical trials on Diarrhea. Report includes an overview of trial...

  • Digestive System Disorder
  • North America
  • United States
  • World
  • Furiex Pharmaceuticals, Inc.
  • 2.3 DEFINITIONS OF PROCEDURES COVERED IN THE REPORT

IN GASTRIC BYPASS PROCEDURE, THE STOMACH IS STAPLED INTO ## PIECES, ONE SMALL AND ONE LARGE.

  • Digestive System Disorder
  • Hospital
  • Medical Device
  • Prosthesis
  • Sterilization Equipment
  • 2.3 DEFINITIONS OF PROCEDURES COVERED IN THE REPORT

IT is recommended for patients with Body Mass Index (BMI)≥ ## or BMI ≥ ## with co morbidities such as type ## Bariatric Procedures IN GASTRIC BYPASS PROCEDURE, THE STOMACH IS STAPLED INTO ## PIECES, ONE SMALL AND ONE LARGE.

  • Acrylonitrile
  • Digestive System Disorder
  • Hospital
  • Medical Device
  • Sterilization Equipment
  • Trial Results
  • Trial Results

The prominent features of this report are - ##.

  • Digestive System Disorder
  • World
  • AstraZeneca PLC
  • POZEN Inc.
  • Takeda Pharmaceutical Company Limited
  • Proportion of Hepatorenal Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2015*
  • Clinical Trials by G7 Countries: Proportion of Hepatorenal Syndrome to Gastrointestinal Clinical Trials

Hepatorenal Syndrome Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Hepatorenal Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Hepatorenal Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials...

  • Digestive System Disorder
  • World
  • Cumberland Pharmaceuticals Inc.
  • Ferring International Center S.A.
  • La Jolla Pharmaceutical Company
  • PROPORTION OF CORROSIVE ESOPHAGITIS (EROSIVE ESOPHAGITIS) TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2015*
  • Clinical Trials by G7 Countries: Proportion of Corrosive Esophagitis (Erosive Esophagitis) to Gastrointestinal Clinical Trials

Corrosive Esophagitis (Erosive Esophagitis) Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Corrosive Esophagitis (Erosive Esophagitis) Global Clinical Trials Review, H1, 2015" provides data on the Corrosive Esophagitis (Erosive Esophagitis) clinical trial scenario. This report provides...

  • Clinical Trial
  • Digestive System Disorder
  • World
  • Market Size
  • Takeda Pharmaceutical Company Limited
  • 2.3 DEFINITIONS OF PROCEDURES COVERED IN THE REPORT

IN GASTRIC BYPASS PROCEDURE, THE STOMACH IS STAPLED INTO ## PIECES, ONE SMALL AND ONE LARGE.

  • Digestive System Disorder
  • Hospital
  • Medical Device
  • Prosthesis
  • Sterilization Equipment
  • 2.3 DEFINITIONS OF PROCEDURES COVERED IN THE REPORT

IT is recommended for patients with Body Mass Index (BMI)≥ ## or BMI ≥ ## with co morbidities such as type ## Bariatric Procedures IN GASTRIC BYPASS PROCEDURE, THE STOMACH IS STAPLED INTO ## PIECES, ONE SMALL AND ONE LARGE.

  • Acrylonitrile
  • Digestive System Disorder
  • Hospital
  • Medical Device
  • Sterilization Equipment